A main theory behind the cause of Alzheimer’s disease is the build-up of the protein amyloid-beta in the brain. Researchers from the University of Cincinnati provide evidence suggesting it’s the ...

The amyloid theory just won’t die. In fact, by approving Biogen's new Alzheimer's disease drug, the FDA has just resurrected it for a long and healthy future. This is great news for Biogen, but it ...

A year ago, Alzheimer’s researchers expressed guarded optimism. The first new drug in nearly two decades was about to hit the market, and pharmaceutical companies had potentially stronger drugs in the ...

Alzheimer's disease is a form of progressive dementia that we've labored to figure out for decades. Scientists made some headway with the amyloid hypothesis of Alzheimer's disease, but progress is ...

It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease. For two decades, Alzheimer's research has focused solely on the idea that amyloid plaques on the ...

LONDON (Reuters) - Diabetes drugs that also promote weight loss such as Novo Nordisk’s Ozempic, becoming a darling of celebrities and investors, are being studied to tackle some of the most ...

This article is the fourth installment in my series on Alzheimer’s disease. Read more about Alzheimer’s disease in part 1, part 2, and part 3 of the series. The pharmaceutical and biotech companies, ...

Research on Alzheimer's disease is one of the hottest topics in the biological sciences today. In 1992, for instance, two Alzheimer's papers made it into the list of the top 25 cited papers of the ...

The hallmark pathology of Alzheimer's is accumulation of a protein called amyloid in the brain. Many researchers have assumed that these aggregates, or plaques, are simply a byproduct of some other ...

Three decades after the presumed cause of Alzheimer’s disease was identified, a Japanese company little known outside of the pharmaceutical industry has become the first drugmaker to prove the ...

After many decades of little or no progress in treating the dementia associated with Alzheimer's, a new drug now offers hope to patients and caregivers. Lecanemab, announced late last month, was found ...